期刊文献+

EphrinA1、ERα和ERβ在乳腺癌中的表达及其意义 被引量:3

Protein expressions of EphrinA1,ERα and ERβ in breast carcinomas and their significance
下载PDF
导出
摘要 目的:研究乳腺癌中EphrinA1、ERα和ERβ蛋白的表达及其意义。方法:用免疫组织化学SP法检测130例乳腺癌组织中EphrinA1、ERα及ERβ蛋白的表达水平,研究其与各临床病理因素的关系。结果:130例乳腺癌组织中EphrinA1、ERα和ERβ的阳性率分别为59.23%、63.08%和53.08%。EphrinA1蛋白在乳腺癌的阳性表达率与临床分期、淋巴结转移和组织学分级显著相关(P<0.05);ERα蛋白阳性表达率与各临床病理因素均无显著相关(P>0.05);ERβ蛋白的阳性表达与组织学分级显著相关(P<0.05)。EphrinA1在乳腺癌中表达与ERα表达无显著相关(P>0.05);EphrinA1蛋白在乳腺癌中表达与ERβ蛋白显著相关(P<0.05)。结论:EphrinA1、ERα和ERβ可能在乳腺癌的发生发展中发挥重要作用。联合检测可评估乳腺癌的生物学行为,并指导临床用药和预测预后。 Objective:The protein expressions of EphrinA1, ERo~ and ER~ and their significance were studied in breast carcinomas. Methods:The protein expressions of EphrinA1, ERct and ER~ were detected by immunohistoehem- istry SP method in 130 breast carcinoma samples. Then their relationship to clinicopathologieal factors were studyed. Results:The total positive rates of EphrinA1, ERa and ERB were 59.23 %, 63.08 % and 53.08 % respectively among the 130 breast carcinoma cases. The positive expressions of EphrinA1 protein were associated with clinical stage, lymph node metastasis and histological grade( P 〈 0.05 ). The protein expressions of ERa was not associated with all the clinic -pathological factors( P 〉 0.05 ). The positive expression of ERi3 protein were associated with histological grade( P 〈 0.05 ). The positive rate of EphrinA1 was not related with ERa( P 〉 0.05 ). The exprssion of EphrinA1 protein was significantly correlated with the expression of ERI]( P 〈 0.05 ), the positive rate of EphrinA1 protein ex- pression increased when the positive rate of ER~ protein increased. Conclusion:EphrinA1 ,ERct and ERB may be in- volved in carcinogenesis and development procedures of breast carcinoma. The combined detection of EphrinA1, ERa and ERr3 can help to predict the clinical and pathologic characteristics of breast carcinoma. It is an important index to guide treatment, and predictive factors for breast cancer.
出处 《现代肿瘤医学》 CAS 2014年第4期833-836,共4页 Journal of Modern Oncology
关键词 EPHRINA1 ERA EB 乳腺癌 免疫组织化学 EphrinA1 ERa ER breast carcinoma immunohistochemistry
  • 相关文献

参考文献11

  • 1赵玉斌,张少华,王金清,蔡学海,纪维忠,张积仁.乳腺癌组织EphA2和EphrinA1蛋白表达及其临床意义的探讨[J].中华肿瘤防治杂志,2011,18(7):513-516. 被引量:12
  • 2Ogawa K,Pasqualini R,Lindberg RA,et al.The EphrinA1 ligand and its receptor,EphA2,are expressed during tumor neovascularization[J].Oncogene,2000,19 (52):6043-6053.
  • 3Speirs V,Adams IP,Walton DS,et al.Identification of wild-type and exon5 deletion variants of estrogen receptorβ in normal human mammary gland[J].Clin Endocrinol Metab,2000,85 (40):1601-1605.
  • 4Dotzlaw H,Leygue E,Watson PH,et al.Expression of estrogen receptor-beta in human breast tumors[J].Clin Endocrinol Metab,1997,82(10):2371-2374.
  • 5Nakamura R,Kataoka H,Sato N,et al.EphA2/EFNA1 expression in human gastric cancer[J].Cancer Sci,2005,96 (1):42-47.
  • 6Straume O,Akslen LA.Importance of vascular phenotype by basic fibroblast growth factor,and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and EphrinA1/EphA2 on melanoma progression[J].Am J Pathol,2002,160(3):1009-1019.
  • 7Easy DJ,Bennett DC.Protein tyrosine kinases in malignant melanoma[J].Melanoma Res,2000,10(5):401-411.
  • 8李道旺,马成民,王红群,杨枫.p53、ER和PR在乳腺癌中的表达及其临床和预后意义[J].安徽医药,2008,12(10):926-928. 被引量:8
  • 9Fujimoto J,Hirose R,Sakaguchi H,et al.Clinical significance of expression of estrogen receptor alpha and beta mRNAs in ovarian cancers[J].Oncology,2000,58 (4):334.
  • 10Dotzlaw H,Leygue E,Watson PH,et al.Estrogen receptor-β messenger RNA expression in human breast tumor biopsies:relationship to steroid receptor staus and regulation by progestins[J].Cancer Res,1999,59 (3):529-532.

二级参考文献15

  • 1韩丽萍,董子明,乔玉环,Jahn M.Nesland,索振河.卵巢癌组织中EphA2受体蛋白的表达[J].郑州大学学报(医学版),2005,40(2):308-311. 被引量:9
  • 2周才明,黎绍基,何健标.乳腺癌淋巴结转移与ER,PR,Ki67,p53表达的相关分析及临床意义[J].广东医学,2007,28(4):510-512. 被引量:12
  • 3王丽茹,张晨瑶,彭中宜.乳腺癌组织中PTEN和Survivin及p53的表达及相关性研究[J].中华肿瘤防治杂志,2007,14(3):193-195. 被引量:7
  • 4刘鹏,刘艳,张瑾.原发性乳腺癌HER-2与P53蛋白表达的相关性研究[J].中华医学杂志,2007,87(26):1844-1847. 被引量:2
  • 5Yamaguchi S, Tatsumit T, Takeharat T, et al. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines[J]. Cancer, 2007, 110(7):1469-1477.
  • 6Zeng G, Hu Z, Kinch M S, et al. High-level expression of EphA2 receptor tyrosinekinase in prostatic intraepithelial neoplasia[J]. AmJ Pathol, 2003,163(6): 2271-2276.
  • 7Choik, Creighton C J, Stivers D, et al. Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations[J]. PlosOne, 2007,2(11):e1226.
  • 8Valladaresa, Hernandezn G, Gomez F S, et al. Genetic expres sion profiles and chromosomal alterations in sporadic breast cancer in Mexican women[J].Cancer Genet Cytogene, 2006, 170(2) : 147-151.
  • 9Zelinske D P, Zantek N D, Stewart J C, et al. EphA2 overex pression cause tumorgenesis of mammary epithelial cells[J]. Cancer Res, 2001,61(5):2301-2306.
  • 10Ogawa K, Pasqualini R, Lindberg R A, et al. The ephrin AI ligand and its receptor, EphA2, are expressed during tumor neovascularization[J]. Oncogene, 2000,19(52) :6043-6053.

共引文献18

同被引文献28

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部